	US 12,226,459 B2
	Collagen hydrolysate for use in prevention and/or treatment of post intensive care syndrome (pics)
Barbara De Klerk-Engels, Ghent (BE); Elien Monique Gevaert, Ghent (BE); Praneeth Reddy Kuninty, Ghent (BE); Janne Prawitt, Ghent (BE); and Nicolina Virgilio, Ghent (BE)
Assigned to ROUSSELOT B.V., Ghent (BE)
Appl. No. 18/695,013
Filed by ROUSSELOT B.V., Ghent (BE)
PCT Filed Aug. 30, 2023, PCT No. PCT/EP2023/073847 § 371(c)(1), (2) Date Mar. 25, 2024, PCT Pub. No. WO2024/047134, PCT Pub. Date Mar. 7, 2024.
Claims priority of application No. 2022/5691 (BE), filed on Aug. 31, 2022.
Prior Publication US 2024/0415938 A1, Dec. 19, 2024
Int. Cl. A61K 38/39 (2006.01); A61K 9/14 (2006.01); A61K 38/01 (2006.01); A61P 43/00 (2006.01); C07K 14/78 (2006.01)

CPC A61K 38/39 (2013.01) [A61K 9/14 (2013.01); A61K 38/01 (2013.01); A61K 38/014 (2013.01); A61P 43/00 (2018.01); C07K 14/78 (2013.01); A23V 2250/5422 (2013.01); A23V 2250/55 (2013.01)]

10 Claims

1. A method for improving the recovery of a subject after intensive care unit stay comprising administering a collagen hydrolysate to the subject, wherein the collagen hydrolysate is derived from one or more of porcine, bovine or fish and has an average molecular weight of no more than 5,000 Daltons (Da), and wherein improving the recovery of the subject after intensive care unit stay comprises prevention and/or treatment of post-intensive care syndrome (PICS).